REVIA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Revia, and what generic alternatives are available?
Revia is a drug marketed by Teva Womens and is included in one NDA.
The generic ingredient in REVIA is naltrexone hydrochloride. There are nineteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the naltrexone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Revia
A generic version of REVIA was approved as naltrexone hydrochloride by BARR on May 8th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REVIA?
- What are the global sales for REVIA?
- What is Average Wholesale Price for REVIA?
Summary for REVIA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 46 |
| Patent Applications: | 4,481 |
| DailyMed Link: | REVIA at DailyMed |
US Patents and Regulatory Information for REVIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Womens | REVIA | naltrexone hydrochloride | TABLET;ORAL | 018932-001 | Nov 20, 1984 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
